xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
222.—(1) Regulation 331 is amended as follows.
[F1(2) In paragraph (1)—
(a)for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation”;
(b)in sub-paragraph (c), at the beginning, insert “in the case of a product authorised under a UKMA(NI) or UKMA(UK),”.]
[F2(3) In paragraph (4)—
(a)for sub-paragraph (b) substitute—
“(b)the guidelines on good distribution practice—
(i)in the case of Great Britain, published under, or that apply by virtue of, regulation C17;
(ii)in the case of Northern Ireland, published by the European Commission in accordance with Article 84 of the 2001 Directive;”;
(b)after sub-paragraph (c) insert—
“(d)Schedule 12A; and
(e)the Implementing Regulation (as defined in regulation 177(5)).”.]
Textual Amendments
F1Reg. 222(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 181(a)
F2Reg. 222(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 181(b)
Commencement Information
I1Reg. 222 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1